RecruitingPhase 2NCT07279714

Fisetin in Mild Alzheimer's Disease

Fisetin Intervention Study in Mild Alzheimer's Disease


Sponsor

Sunnybrook Health Sciences Centre

Enrollment

5 participants

Start Date

Jan 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.


Eligibility

Min Age: 60 Years

Inclusion Criteria3

  • Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
  • Moca score of 11 or higher
  • Stable psychotropics and cognitive enhancing medications

Exclusion Criteria12

  • Known hypersensitivity or allergy to fisetin
  • Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
  • Unstable medical disorders
  • Ongoing treatment for active infection with antibiotics/antifungals
  • Ongoing treatment for cancer
  • Active alcohol or substance use disorder
  • Recent active bleeding
  • Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
  • Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
  • Other neurologic or neurodegenerative conditions impacting cognition
  • Active Major Depressive Episode, active suicidal thoughts or psychosis
  • Any thing that would preclude the ability to undergo an MRI scan

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERFisetin

Fisetin 20mg/kg/day


Locations(1)

Sunnybrook Research Institute

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07279714


Related Trials